Treprostinil diolamineProduct ingredient for Treprostinil

Treprostinil is a stable tricyclic analogue of prostacyclin³ that promotes the vasodilation of pulmonary and systemic arterial vascular beds and the inhibition of platelet aggregation.^5,6,7 It reduces symptoms in patients with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease.^5,6 The first agent approved for the treatment of PAH was epoprostenol, a synthetic prostacyclin that significantly increases patients' quality of life. However, the use of epoprostenol is limited due to its short half-life (3-5 min) and instability at room temperature.^3,4 The use of more stable alternatives such as treprostinil provides patients with PAH with more treatment options.

Treprostinil was approved by the FDA in 2002 for the treatment of pulmonary arterial hypertension.⁶ It is available in the following routes of administration: subcutaneous, intravenous, inhaled and oral. The first generic form of treprostinil became available in 2019.⁴